Using the immune system to treat and prevent cancer.
Anixa is a clinical-stage biotechnology company working on cancers that have been difficult to treat. Two programs are in the clinic: a CAR-T therapy for recurrent and resistant ovarian cancer and a vaccine for the treatment and prevention of breast cancer.
An approach built around the immune system.
Our work is focused on cancers where current treatment options are limited. We develop our programs alongside leading research and clinical institutions, which lets us advance several different scientific approaches at the same time.
Two programs in the clinic
A CAR-T therapy for ovarian cancer and a vaccine for breast cancer. Both have generated human data.
Developed with leading institutions
Active and previous collaborations with Cleveland Clinic, Moffitt Cancer Center, The Wistar Institute, the U.S. Department of Defense, and the National Cancer Institute.
Treatment and prevention
The breast cancer vaccine is being studied for treating existing cancer, preventing recurrence in cancer survivors, and for reducing the chance that it develops in the first place.
Two programs, two ways of using the immune system.
An FSHR-targeted CAR-T therapy for ovarian cancer
A therapy that reprograms a patient’s own T-cells to recognize Follicle-Stimulating Hormone Receptor (FSHR), a receptor found on ovarian tumors. It is delivered directly into the abdominal cavity so it can act on tumors there.
- FSHR targeting. Uses follicle-stimulating hormone as a natural ligand to find tumor cells.
- Intraperitoneal delivery. Administered into the abdomen rather than the bloodstream.
- Dose escalation underway. The protocol has been amended to allow higher dose levels.
A vaccine that targets a protein linked to breast cancer
The vaccine targets “retired” proteins: ones the body makes only at certain life stages and no longer needs in most adults, but that reappear in certain cancers. It has completed Phase 1.
- Breast cancer vaccine. Targets alpha-lactalbumin and is being prepared for Phase 2.
- Studied with Keytruda. No added side effects were seen in the combination.
How far each program has come.
A short summary of each program and the stage it has reached. See the pipeline page for more details.
What we have learned in patients so far.
Both programs have been studied in people, not only in the lab. The figures below come from what has been publicly disclosed about the trials to date.
Phase 1, dose escalation in progress
An FSHR-targeted CAR-T therapy delivered directly into the abdominal cavity, studied in heavily pre-treated women with recurrent ovarian cancer.
- Encouraging survival observations have been reported.
- Multiple patients survived more than a year past treatment.
- Therapy has been safe and well tolerated. No observations of cytokine release syndrome.
Phase 1 complete, preparing for Phase 2
An alpha-lactalbumin vaccine being studied to treat breast cancer, to prevent recurrence in survivors, and to lower the risk of disease in people at high risk.
- Phase 1 study met primary endpoints.
- Protocol-defined immune responses were observed in 74% of trial participants.
- Vaccine demonstrated safety and tolerability and combination with Keytruda did not create additional side effects.
For more detail on the company and its clinical trials, see the corporate presentation.
View the corporate presentationA breast cancer vaccine that could one day prevent the disease before it starts.
Fox News · on Anixa's breast cancer vaccine
Developed with leading cancer institutions and partners.
Each program is developed with a research or clinical institution and partner that brings deep scientific expertise and access to patient care, so Anixa can advance more than one program at a time.
Selected media coverage.
A curated set of recent media coverage, analyst interviews, and presentations about the science behind Anixa’s programs.
Recent news from Anixa.
FAQs
A few things investors and newcomers ask most often. For filings and disclosures, visit the investor relations site.
What stage are Anixa's programs in?
How is the vaccine meant to prevent cancer?
Who does Anixa develop its programs with?
Where can I find financial filings and disclosures?
Follow Anixa's programs as they progress.
Get press releases and trial updates by email — subscribe on our investor relations site, where you can also opt in to SEC filings.